Adverse drug reactions (ADRs) account for a large proportion of hospitalizations among
adults and are more common in multimorbid patients, worsening clinical outcomes and …

Summary Background Pharmacogenomics (PGx) holds promise to revolutionize modern
healthcare. Although there are several prospective clinical studies in oncology and …

The CYP2C19 gene is frequently included in different pharmacogenomic panels tested in
clinical practice, due to its involvement in the metabolism of a myriad of frequently …

Azathioprine is commonly used as an immunosuppressive antimetabolite in the treatment of
acute lymphoblastic leukemia, autoimmune disorders (such as Crohn's disease and …

Chronic kidney disease (CKD) is a global health issue. Kidney failure patients may undergo
a kidney transplantation (KTX) and prescribed an immunosuppressant medication ie …

An increasing number of economic evaluations are published annually investigating the
economic effectiveness of pharmacogenomic (PGx) testing. This work was designed to …

There is growing evidence that pharmacogenetic analysis can improve drug therapy for
individual patients. In Switzerland, pharmacists are legally authorized to initiate …

Aims Genetic testing can be used to improve the safety and effectiveness of commonly
prescribed medicines—a concept known as pharmacogenetics. This study aimed to quantify …

Cardiovascular diseases (CVDs) remain one of the leading causes of morbidity and
mortality worldwide, with genetics being a major risk factor. Genetic cardiovascular disease …

Background Clopidogrel is a widely prescribed prodrug that requires activation via specific
pharmacogenes to exert its anti-platelet function. Genetic variations in the genes encoding …